CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
Hand-out
Press Releases
CARsgen Therapeutics  
February 25, 2025

CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China

SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK, "CARsgen Therapeutics"), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and

avatar profile Olean Times Herald

Olean Times Herald


Local & Social